Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,445 total articles
Invivyd, Inc. announced the grant of stock options totaling 277,500 shares to ten newly hired non-executive employees as inducements under Nasdaq Listing Rule 5635(c)(4). These options have an exercise price of $0.535, matching the stock's closing price on July 31, 2026, with a four-year vesting period and a 10-year term. This move aims to attract …
Rhythm Pharmaceuticals announced its Q2 2026 financial results, highlighting a robust U.S. launch of IMCIVREE for acquired hypothalamic obesity, with over 400 patient starts since FDA approval. Net product revenue reached $71.3 million globally, a 19% sequential increase, driven by strong U.S. sales and growing patient reimbursement. The company al…
Larimar Therapeutics reported encouraging long-term safety and efficacy data for nomlabofusp in an open-label study for Friedreich's ataxia, submitted the first module of a rolling Biologics License Application with the FDA seeking accelerated approval, and plans to start a global Phase 3 confirmatory study in Q3 2026. The company has a strong cash…
Descartes Systems Group will announce its second quarter fiscal 2027 financial results after market close on September 10, 2026. The company's executive management will host a conference call and webcast to discuss the results, providing investors and stakeholders with insight into its performance in the logistics technology sector.
RYTHM, Inc. reported robust financial results for Q2 2026, with revenue from continuing operations reaching $23 million, up 73% quarter-over-quarter. The company achieved net income of $1.2 million and an adjusted EBITDA of $6.4 million, marking a significant turnaround from breakeven in the prior quarter. Growth in THC beverage shipments and new s…
Aclarion, Inc. announced that its Nociscan platform for identifying the source of chronic low back pain is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, the first site in Indiana to offer this technology. This expansion marks growth in Aclarion's provider network and aligns the company with a nationally recognized neuros…
iBio, a clinical-stage biotechnology company focused on long-acting antibody therapeutics for obesity and cardiometabolic diseases, has appointed Dr. Molly Carr as Chief Medical Officer. Dr. Carr brings over 30 years of experience in endocrinology and metabolic disease, having held senior roles at major biopharmaceutical companies. Her leadership i…
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focusing on novel FASN inhibitors targeting metabolic and fibrotic pathways, announced management's participation in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026.
CAMP4 Therapeutics completed the second closing of a $100 million private placement, raising approximately $50.1 million to fund clinical development of CMP-002, a lead antisense oligonucleotide targeting SYNGAP1-related disorder, and other early-stage programs. The company aims to initiate a Phase 1/2 trial in Australia, advancing its pipeline of …
Shoals Technologies Group, Inc., a leader in electrical infrastructure solutions for the energy transition, reported strong Q2 2026 financial results, with revenue increasing 47.4% to $163.4 million and a record backlog and awarded orders of $801.4 million. Although gross margin declined primarily due to operational inefficiencies from transitionin…
X-Energy's subsidiary TRISO-X has acquired an additional 70 acres adjacent to its Oak Ridge, Tennessee nuclear fuel campus, expanding its total footprint to approximately 180 acres. This expansion supports construction and long-term growth plans for advanced nuclear fuel fabrication facilities and research capabilities, reinforcing the region’s lea…
First Watch Restaurant Group, Inc. released its Q2 2026 financial results, highlighting a 15.2% increase in total revenues to $354.7 million, same-restaurant sales growth of 3.4%, and net income rising to $2.3 million. The company opened 18 new restaurants and updated its fiscal 2026 outlook projecting revenue growth between 12.5% to 14%, and adjus…
Arvinas, Inc. announced the FDA approval of VEPPANU, the first-ever PROTAC degrader approved for breast cancer treatment, and completed a global licensing deal with Rigel Pharmaceuticals. The company reported strong financial results for Q2 2026, driven by increased revenues from partnerships and milestones. Clinical progress includes ongoing Phase…
Odyssey Therapeutics reported its second quarter 2026 results, highlighting positive Phase 2a trial data for its OD-001 program to be presented at a major gastroenterology conference in October. The company plans to initiate Phase 2b monotherapy and Phase 2a combination trials for OD-001 in the second half of 2026, alongside preparing a CTA filing …
TOP Financial Group Limited announced a major strategic initiative to incorporate advanced artificial intelligence technologies across its core brokerage and financial technology businesses. The company plans to develop AI infrastructure encompassing software, hardware, cloud computing, and AI agent deployment to enhance operational efficiency, use…
Insight Molecular Diagnostics Inc. announced it will release its second quarter 2026 financial results on August 10, 2026, followed by a live webinar to discuss the results. The company will also participate in the 11th Annual Needham Virtual MedTech & Diagnostics conference on August 11, 2026, holding one-on-one investor meetings virtually.
Strata Critical Medical, Inc. announced second-quarter 2026 financial results, showing a 60.7% year-over-year revenue increase to $72.5 million. The growth was fueled by organic expansion in logistics and significant contributions from recent clinical business acquisitions. Adjusted EBITDA nearly tripled year-over-year to $7.9 million, with margin …
Aeluma, a NASDAQ-listed semiconductor company, announced the appointment of Jason Taylor as Senior Director of Program and Project Management. With nearly 30 years of semiconductor experience, Taylor will lead program management efforts to commercialize Aeluma's compound semiconductor photonic technologies. This strategic hire comes amid growing co…
Lisata Therapeutics announced the termination of its merger agreement with Kuva Labs and has filed a lawsuit against Kuva for breach of contract seeking damages and a termination fee. The company is actively evaluating strategic alternatives to maximize shareholder value, including possible mergers, acquisitions, asset sales, or liquidation. To con…
Beam Therapeutics announced significant progress in Q2 2026, including dosing the first patient in a pivotal cohort for BEAM-302 in alpha-1 antitrypsin deficiency, completion of dosing in the BEACON trial for sickle cell disease with risto-cel, FDA clearance for BEAM-304 clinical trial in phenylketonuria, and a strong cash position supporting opera…
Certara, Inc. reported a 1% increase in total revenue year-over-year for Q2 2026, with software revenue growing 4% while services revenue declined 3%. The company posted a net loss of $6.1 million due to higher operating expenses and absence of prior year favorable adjustments. Certara completed a $100 million share repurchase program and authorize…
Dianthus Therapeutics announced DNTH312, an internally developed first-in-class bifunctional fusion protein combining claseprubart and TACI to potently inhibit aC1s and BAFF/APRIL pathways. DNTH312 demonstrates comparable potency and half-life to claseprubart and aims to be Phase 1 ready by the end of 2027. This innovative therapy targets severe au…
LGI Homes, Inc. reported strong results for the second quarter of 2026, with an 8.8% increase in home deliveries year-over-year and revenues reaching $516 million. Homebuilding gross margins surpassed previous guidance, and the company reduced its debt significantly, improving its debt-to-capital ratio. Based on this strong performance, LGI Homes r…
Tiziana Life Sciences announced that CEO Ivor Elrifi purchased 667,000 shares at $1.00 each, increasing his total holdings to over 4.4 million shares. The company is advancing its lead candidate, intranasal foralumab, a novel fully human anti-CD3 monoclonal antibody targeting neuroinflammatory diseases like non-active secondary progressive multiple…
Tower Semiconductor reported record revenue of $460 million and net profit of $91 million for Q2 2026, reflecting strong year-over-year growth of 24% and 95% respectively. The company anticipates even higher revenue in Q3 2026 at $520 million, up 31% year-over-year. Tower also announced substantial capacity expansions and raised its 2028 revenue ta…
